☆ 4.8 Article

Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians

Justin T. Low et al.

Summary: This report summarizes the statistics of incidence, survival, and mortality rates for primary malignant and nonmalignant brain and other CNS tumors in the United States, highlighting differences among different age groups, genders, and races.

NEURO-ONCOLOGY PRACTICE (2022)

Add to Collection

Review Oncology

Epidemiology of Glioblastoma Multiforme-Literature Review

Szymon Grochans et al.

Summary: Glioblastoma multiforme (GBM) is a highly aggressive malignancy with a median overall survival of approximately 15 months. This review analyzes the pathogenesis and epidemiological data of GBM, including age, gender, and tumor location. The data suggest that GBM is a higher-grade primary brain tumor and is significantly more common in men. Despite advancements in medicine, the risk of being diagnosed with glioma increases with age and median survival remains low. Additionally, the influence of stimulants, certain medications (such as NSAIDs), cell phone use, and exposure to heavy metals on GBM is difficult to determine clearly.

CANCERS (2022)

Add to Collection

Review Biology

Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review

Lapo Bonosi et al.

Summary: Liquid biopsies have emerged as an innovative tool for the early diagnosis, monitoring, and prognosis of gliomas. Next-generation sequencing technologies have led to improved accuracy and reduced costs, providing a molecular profile of cancer and leading to better survival outcomes. This paper focuses on the current clinical application of liquid biopsy in the early diagnosis and prognosis of cancer, introduces NGS-related methods, reviews recent progress, and summarizes challenges and future perspectives.

LIFE-BASEL (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

Tianrui Yang et al.

Summary: Immune checkpoint inhibitors have revolutionized tumor immunotherapy, but face challenges in the treatment of glioblastoma due to its unique immunosuppressive characteristics. Recent clinical studies are focusing on combination therapies involving standard treatments, targeted therapies, and other immunotherapies to improve outcomes for patients with GBM.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Julianne D. Twomey et al.

Summary: ICIs, targeting PD-1 or PD-L1, have become a new standard-of-care for many cancer indications, approved by the FDA. This review focuses on their clinical indications, companion diagnostics, and strategies for identifying predictive biomarkers for guiding their clinical use.

AAPS JOURNAL (2021)

Add to Collection

Review Oncology

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway

Thamiris Becker Scheffel et al.

Summary: Glioblastoma is a highly malignant subtype of glioma, and the immune landscape within the tumor microenvironment plays a crucial role in influencing therapy outcomes. The presence of multiple immunosuppression pathways, particularly the adenosine pathway, poses significant obstacles to immune-based cancer therapies and can contribute to treatment resistance. Research focusing on immune checkpoints and the adenosine pathway may provide insights into potential targets for improving tumor treatment strategies.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

So Yeon Oh et al.

Summary: The study revealed that high levels of sPD-L1 in cancer patients were associated with progressive disease and worse prognosis, as well as positively correlated with neutrophil to lymphocyte ratios and negatively correlated with lymphocyte proportions and total numbers.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma

Maximilian J. Mair et al.

Summary: Changes in systemic inflammation markers including soluble PD-L1 are observable in patients with recurrent glioma under bevacizumab-based treatment and differ between WHO grade II-III glioma and GBM.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Review Cell Biology

Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects

Xin Wang et al.

Summary: For recurrent glioblastoma (rGB) patients, neoadjuvant anti-PD-1 therapy followed by surgery and adjuvant anti-PD-1 therapy can significantly improve overall survival. Additionally, tumor-specific peptide vaccination or CAR-T cell therapy has shown promise for treating rGB patients. Effective predictive biomarkers for clinical efficacy are needed, along with efforts to enhance T cell function through engineering techniques.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Oncology

Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives

Lidia Gatto et al.

Summary: Glioblastoma is the most common primary tumor of the central nervous system, characterized by challenges and limitations. Liquid biopsy offers an attractive minimally invasive solution to support glioblastoma management at different stages.

ONCOLOGIST (2021)

Add to Collection

Review Genetics & Heredity

Recent Advances in Liquid Biopsy of Brain Cancers

Yunyun An et al.

Summary: Brain cancers are a major cause of death worldwide, with varied survival rates depending on tumor type. Liquid biopsy assays using peripheral blood or cerebrospinal fluid have shown favorable characteristics for diagnosis, tumor subtyping, relapse prediction, and prognosis monitoring in brain cancers, making a significant step towards clinical benefits for patients.

FRONTIERS IN GENETICS (2021)

Add to Collection

Review Cell Biology

Sex-Specific Differences in Glioblastoma

Anna Carrano et al.

Summary: Sex differences exist in brain tumors, with males having higher incidence and worse outcomes in GBM compared to females. Estrogen plays a protective role in GBM, while upregulation of androgen receptors and testosterone may have detrimental effects. Hormones and the immune system play important roles in the GBM microenvironment.

CELLS (2021)

Add to Collection

Review Oncology

Circulating biomarkers in patients with glioblastoma

Juliana Muller Bark et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Plasma PD-L1 levels according to histologic grade and IDH status in patients with gliomas.

Santiago Cabezas-Camarero et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas

Shujun Liu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Instruments & Instrumentation

Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management

Prashant G. Upadhaya et al.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2020)

Add to Collection

Review Oncology

Management of glioblastoma: State of the art and future directions

Aaron C. Tan et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Multidisciplinary Sciences

Revisiting the PD-1 pathway

Nikolaos Patsoukis et al.

SCIENCE ADVANCES (2020)

Add to Collection

Review Immunology

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Muhammad Khan et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Cell Biology

PD-L1 degradation pathway and immunotherapy for cancer

Qian Gou et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Article Oncology

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Maximilian J. Mair et al.

ESMO OPEN (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016

Quinn T. Ostrom et al.

NEURO-ONCOLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

The Prognostic and Therapeutic Value of PD-L1 in Gliomaa

Ruo Qiao Chen et al.

FRONTIERS IN PHARMACOLOGY (2019)

Add to Collection

Article Hematology

Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis

Haorui Shen et al.

HEMATOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

Franz L. Ricklefs et al.

SCIENCE ADVANCES (2018)

Add to Collection

News Item Multidisciplinary Sciences

Cancer immunologists scoop medicine Nobel prize

Heidi Ledford et al.

NATURE (2018)

Add to Collection

Review Oncology

Adult Glioblastoma

Brian M. Alexander et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI

Joseph P. Antonios et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Multidisciplinary Sciences

The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis

Song Xue et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Multidisciplinary Sciences

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst et al.

NATURE (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.